Explainer
Evidence-led entry points for non-clinicians. What is a GLP-1 receptor agonist, what does ATC A10BX mean, why are some peptides legal in Russia but not the EU.
Weight Regain After Stopping GLP-1 Drugs
A 2026 Bayesian meta-analysis maps how quickly body weight returns after stopping semaglutide or tirzepatide and what the trajectory looks like over time.
GLP-1 in PCOS: the fertility evidence gaps
A scientific debate in Clinical Nutrition ESPEN spotlights how much the field still does not know about semaglutide, PCOS, and fertility.
Tirzepatide powder: what the label says
Forum questions about reconstituting tirzepatide powder reveal a key fact: FDA-approved tirzepatide is supplied ready-to-inject, not as a lyophilized powder.
Tirzepatide vs care in early T2D at 2 years
A 2-year trial in Annals of Internal Medicine finds tirzepatide reduces HbA1c and weight more than intensified conventional care in early T2D.
Tirzepatide vs semaglutide: meta-analysis
A 2026 meta-analysis in Clinical Obesity pooled head-to-head and indirect trial data comparing tirzepatide and semaglutide for weight loss.
Is CJC-1295/ipamorelin flushing normal?
Facial flushing after CJC-1295 and ipamorelin injections is a known, documented reaction pattern for this peptide class, not an unusual one.
PNPHO nanocarrier for nasal semaglutide
A thermoresponsive PNPHO nanocarrier encapsulated semaglutide at 89% efficiency and improved glucose tolerance in animals. The research is preclinical.
PNPHO nanocarrier for nasal semaglutide
A thermoresponsive PNPHO nanocarrier encapsulated semaglutide at 89% efficiency and improved glucose tolerance in animals. The research is preclinical.
What is KLOW? The peptide blend, explained
KLOW mixes BPC-157, TB-500, GHK-Cu, and KPV. Here is what the evidence for each ingredient shows, and why none of it answers a fracture-healing question.
PT-141 for low libido on GLP-1 drugs
Reduced libido is a reported side effect on GLP-1 drugs. Here is what the evidence shows for PT-141 (bremelanotide) and kisspeptin as options for women.
Retatrutide and DKA in type 1 diabetes
A Cureus 2026 case report: a type 1 diabetes patient self-injected online-sourced retatrutide and developed impending DKA alongside a Shigella infection.
A nasal spray for semaglutide? Not yet
Sydney researchers built a needle-free nasal nanocarrier for semaglutide and tested it in cells and animals, not yet in people.